Companies › Alterome Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALTA2618 AKT1 E17K inhibitor | AKT1 | Phase 1 | Cancer | Dec 2026 |
| ALTA3263 KRAS G12C inhibitor | – | Phase 1 | Cancer | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06533059 | ALTA2618 | Phase 1 | Cancer | Oncology | Dec 2026 |
| NCT06835569 | ALTA3263 | Phase 1 | Cancer | Oncology | May 2029 |
AstraZeneca Merck & Co. (MSD) Roche Laekna Zhejiang Haichang Biotech Atavistik Bio
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.